Acromegalia

Por el personal de Mayo Clinic
15 de septiembre de 2026

Investigación

Los médicos e investigadores de Mayo Clinic estudian una variedad de temas de diagnóstico y tratamiento relacionados con la acromegalia. El equipo de investigación sobre hipófisis, gónadas y glándulas suprarrenales de la División de Endocrinología, Diabetes, Metabolismo y Nutrición se dedica a investigar las afecciones de la glándula pituitaria o hipófisis, las gónadas y las glándulas suprarrenales. La investigación básica del equipo comprende estudios de la estructura y función de los genes relacionados con la hormona del crecimiento, así como del control de la expresión génica de la hormona del crecimiento placentaria. En el ámbito de la investigación clínica, se estudian nuevos medicamentos para el tratamiento de la acromegalia, el hiperaldosteronismo y la deficiencia de la hormona del crecimiento.

Publicaciones

Consulte en PubMed una lista de publicaciones sobre la acromegalia escritas por los médicos de Mayo. PubMed es un servicio de la National Library of Medicine (Biblioteca Nacional de Medicina).

  1. Health Education & Content Services. Acromegaly. Mayo Clinic; 2023.
  2. Acromegaly. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/endocrine-diseases/acromegaly. Accessed Sept. 5, 2024.
  3. Kellerman RD, et al. Endocrine and metabolic disorders. In: Conn's Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Dec. 26, 2020.
  4. Acromegaly. Endocrine Society. https://www.endocrine.org/patient-engagement/endocrine-library/acromegaly. Accessed Sept. 5, 2024.
  5. Melmed S, et al. Treatment of acromegaly. https://www.uptodate.com/contents/search. Accessed Jan. 4, 2021.
  6. Boguslawska A, et al. Genetics of acromegaly and gigantism. Journal of Clinical Medicine. 2021; doi:10.3390/jcm10071377.
  7. Medical review (expert opinion). Mayo Clinic. Sept. 26, 2025.
  8. Gigantism and acromegaly. Merck Manual Professional Version. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/pituitary-disorders/gigantism-and-acromegaly. Accessed Sept. 17, 2025.
  9. Cushing's syndrome. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/endocrine-diseases/cushings-syndrome. Accessed Sept. 19, 2025.
  10. About Marfan syndrome. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/heart-disease/about/marfan-syndrome.html. Accessed Sept. 19, 2025.
  11. Paget's disease of bone. American Academy of Orthopaedic Surgeons. https://orthoinfo.aaos.org/en/diseases--conditions/pagets-disease-of-bone. Accessed Sept. 19, 2025.
  12. Bacino CA, et al. Achondroplasia. https://www.uptodate.com/contents/search. Accessed Sept. 19, 2025.
  13. Weaver syndrome. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/weaver-syndrome/. Accessed Sept. 18, 2025.
  14. Alnaaim S, et al. The potential link between acromegaly and risk of acute ischemic stroke in patients with pituitary adenoma: A new perspective. Acta Neurologica Belgica. 2024; doi:10.1007/s13760-023-02354-3.
  15. Demarchis L, et al. Cancer screening in patients with acromegaly: A plea for a personalized approach and international registries. Reviews in Endocrine and Metabolic Disorders. 2025; doi:10.1007/s11154-025-09957-6.
  16. Kerbel J, et al. Real world data on the epidemiology, diagnosis, and treatment of acromegaly: A registries-based approach. Archives of Medical Research. 2023; doi:10.1016/j.arcmed.2023.102856.
  17. Gadelha MR, et al. Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine. Journal of Clinical Endocrinology & Metabolism. 2025; doi:10.1210/clinem/dgae385.
  18. Melmed S, et al. Clinical biology of the pituitary adenoma. Endocrine Reviews. 2022; doi:10.1210/endrev/bnac010.
  19. Araujo-Castro M, et al. Differences between GH- and PRL-cosecreting and GH-secreting pituitary adenomas: A series of 604 cases. The Journal of Clinical Endocrinology & Metabolism. 2024;109:e2178.
  20. FDA approves new treatment for acromegaly, a rare endocrine disorder. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-acromegaly-rare-endocrine-disorder. Accessed Sept. 30, 2025.